Moderna Inc’s COVID-19 vaccine showed promise against the Delta variant first identified in India in a lab study, with a modest decrease in response compared to the original strain, according to the drugmaker’s website, Report informs referring to Reuters.
The study was conducted on blood serum from eight participants obtained one week after they received the second dose of the vaccine, mRNA-1273.
The vaccine provoked an antibody response against all the variants tested, according to Moderna, but one that remained inferior in all cases to the vaccine’s neutralizing activity against the original coronavirus strain first found in China.
The vaccine was far more effective in producing antibodies against the Delta variant than it was against the Beta variant first identified in South Africa, the data showed.
“These new data are encouraging and reinforce our belief that the Moderna COVID-19 vaccine should remain protective against newly detected variants,” Chief Executive Stéphane Bancel said.